Literature DB >> 2109316

A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression.

C M Coffin1, J T Braun, M R Wick, L P Dehner.   

Abstract

Synaptophysin (SYN) has been identified as an integral membrane glycoprotein of presynaptic vesicles in neurons and neuroendocrine cells, and as a marker for medulloblastoma and other neuronal tumors. SYN expression was studied with a monoclonal antibody (MAb) by the immunoperoxidase technique in 53 medulloblastomas. The expression of neuron-specific enolase (NSE), Leu-7 (LEU), S-100 protein (S100), glial fibrillary acidic protein (GFAP), neurofilament protein (NF), vimentin (VIM), cytokeratin (CKER), and desmin (DES) was also assessed with antisera and MAbs. SYN reactivity was present in 94% of tumors, whereas reactivity with other markers of neuronal differentiation was also observed: NSE (100%) and LEU (83%). Regarding the intermediate filament proteins, 38% of the cases were reactive for VIM, 21% for GFAP, and 9% for DES; none expressed NF or CKER. Eight percent were reactive for S100. Among the 53 cases, the male-female ratio was 1:3; 80% of DES-positive tumors occurred in females. The mean age was 10.5 yr, (60% diagnosed in the first decade; peak age incidence between 5 and 10 yr). Five tumors were discovered in patients older than 20 yr of age. Follow-up showed that 40% of patients developed a recurrence and 47% of patients died of tumor. No statistically significant relationship was demonstrated between patterns of immunoreactivity and prognosis. We conclude that SYN is a useful marker for medulloblastomas, indicating that this tumor is a primitive neuronal-neuroblastic neoplasm. However, it is but one of several immunophenotypic markers expressed by the medulloblastoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2109316

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

Review 1.  Cervical lymph node metastases from remote primary tumor sites.

Authors:  Fernando López; Juan P Rodrigo; Carl E Silver; Missak Haigentz; Justin A Bishop; Primož Strojan; Dana M Hartl; Patrick J Bradley; William M Mendenhall; Carlos Suárez; Robert P Takes; Marc Hamoir; K Thomas Robbins; Ashok R Shaha; Jochen A Werner; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2015-12-29       Impact factor: 3.147

Review 2.  Childhood medulloblastoma: current status of biology and treatment.

Authors:  Laura J Klesse; Daniel C Bowers
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

3.  Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.

Authors:  Noah C Jenkins; Ganesh Rao; Charles G Eberhart; Carolyn A Pedone; Adrian M Dubuc; Daniel W Fults
Journal:  J Neurooncol       Date:  2015-10-30       Impact factor: 4.130

4.  Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors.

Authors:  R T Woodburn; B Azzarelli; J F Montebello; I E Goss
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

Review 5.  Recent advances in embryonal tumours of the central nervous system.

Authors:  Chitra Sarkar; Prabal Deb; Mehar Chand Sharma
Journal:  Childs Nerv Syst       Date:  2005-01-29       Impact factor: 1.475

6.  c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice.

Authors:  Ganesh Rao; Carolyn A Pedone; Cheryl M Coffin; Eric C Holland; Daniel W Fults
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

7.  Age-related immunoreactivity pattern in medulloblastoma.

Authors:  S Patt; C Zimmer
Journal:  Childs Nerv Syst       Date:  1992-09       Impact factor: 1.475

8.  Neuron-associated class III beta-tubulin isotype, retinal S-antigen, synaptophysin, and glial fibrillary acidic protein in human medulloblastomas: a clinicopathological analysis of 36 cases.

Authors:  T Maraziotis; E Perentes; E Karamitopoulou; Y Nakagawa; E C Gessaga; A Probst; A Frankfurter
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.